Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Neuropilin-1 deficiency in vascular smooth muscle cells is associated with hereditary hemorrhagic telangiectasia arteriovenous malformations
Sreenivasulu Kilari, … , Debabrata Mukhopadhyay, Sanjay Misra
Sreenivasulu Kilari, … , Debabrata Mukhopadhyay, Sanjay Misra
Published April 5, 2022
Citation Information: JCI Insight. 2022;7(9):e155565. https://doi.org/10.1172/jci.insight.155565.
View: Text | PDF
Research Article Vascular biology

Neuropilin-1 deficiency in vascular smooth muscle cells is associated with hereditary hemorrhagic telangiectasia arteriovenous malformations

  • Text
  • PDF
Abstract

Patients with hereditary hemorrhagic telangiectasia (HHT) have arteriovenous malformations (AVMs) with genetic mutations involving the activin-A receptor like type 1 (ACVRL1 or ALK1) and endoglin (ENG). Recent studies have shown that Neuropilin-1 (NRP-1) inhibits ALK1. We investigated the expression of NRP-1 in livers of patients with HHT and found that there was a significant reduction in NRP-1 in perivascular smooth muscle cells (SMCs). We used Nrp1SM22KO mice (Nrp1 was ablated in SMCs) and found hemorrhage, increased immune cell infiltration with a decrease in SMCs, and pericyte lining in lungs and liver in adult mice. Histologic examination revealed lung arteriovenous fistulas (AVFs) with enlarged liver vessels. Evaluation of the retina vessels at P5 from Nrp1SM22KO mice demonstrated dilated capillaries with a reduction of pericytes. In inflow artery of surgical AVFs from the Nrp1SM22KO versus WT mice, there was a significant decrease in Tgfb1, Eng, and Alk1 expression and phosphorylated SMAD1/5/8 (pSMAD1/5/8), with an increase in apoptosis. TGF-β1–stimulated aortic SMCs from Nrp1SM22KO versus WT mice have decreased pSMAD1/5/8 and increased apoptosis. Coimmunoprecipitation experiments revealed that NRP-1 interacts with ALK1 and ENG in SMCs. In summary, NRP-1 deletion in SMCs leads to reduced ALK1, ENG, and pSMAD1/5/8 signaling and reduced cell death associated with AVM formation.

Authors

Sreenivasulu Kilari, Ying Wang, Avishek Singh, Rondell P. Graham, Vivek Iyer, Scott M. Thompson, Michael S. Torbenson, Debabrata Mukhopadhyay, Sanjay Misra

×

Figure 8

Smooth muscle cell Nrp1 deletion attenuates flow induced ENG, ALK1, and TGF-β1 but not TNF-α levels in AVF inflow arteries.

Options: View larger image (or click on image) Download as PowerPoint
Smooth muscle cell Nrp1 deletion attenuates flow induced ENG, ALK1, and ...
Immunostaining was performed to assess ENG, ALK1, TGF-β1, and TNF-α levels in the AVF inflow arteries (GA) and contralateral carotid arteries (CA) at 14 days after arteriovenous fistula (AVF) creation. (A, C, E, and G) Representative images of (A) ENG, (C) ALK1, (E) TGF-β1, and (G) TNF-α in GA and CA from NRP1fl/fl (WT) and Nrp1fl/fl/SM22αCre+ (Nrp1SM22KO) mice. All images were captured using 10× magnification. Scale bar: 50 μm. The arrows show the brown positive stain of ENG (A), ALK1 (C), TGF-β1 (E), and TNF-α (G). (B, D, F, and H) The intensity of brown stain positive for ENG (B), ALK1 (D), TGF-β1 (F), and TNF-α (H) index were quantified as described and presented as mean ± SEM of n = 5–7 animals. Two-way ANOVA was performed. *P < 0.05.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts